Cardiovascular disease in lupus: insights and updates
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: With improved management of the classical disease manifestations of systemic lupus erythematosus (SLE), cardiovascular disease (CVD) has emerged as one of the most important causes of morbidity and mortality. This review in particular focuses on progress over the past year in clinical and basic aspects of SLE-driven accelerated atherosclerosis. RECENT FINDINGS: Both subclinical CVD and CV events continue to be recognized at increased frequency in previously unstudied lupus cohorts and populations. Novel associations have been identified between lupus CVD and cognitive impairment, depression, and low-income status. In terms of pathogenesis, there is an ever-increasing focus on the innate immune system and, in particular, type I interferons (IFNs). Recent studies have drawn connections in both human and murine models between neutrophils, plasmacytoid dendritic cells, type I IFNs, and endothelial dysfunction. Whether treatments such as mycophenolate mofetil or statins have a role in prevention of lupus CVD is an area of intensive study. SUMMARY: CVD is a major complication of lupus and is now a leading cause of death among people living with this disease. As such, additional studies are needed in order to identify the most effective preventive strategies and most predictive vascular risk biomarkers. Type I IFNs may play a critical role in lupus CVD pathogenesis, and it is recommended that vascular outcomes be included in ongoing trials testing the efficacy of anti-IFN biologics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood
Clark, S. R., Ma, A. C., Tavener, S. A., McDonald, B., Goodarzi, Z., Kelly, M. M., Patel, K. D., Chakrabarti, S., McAvoy, E., Sinclair, G. D., et al. (2007) · Nature Medicine · doi:10.1038/nm1565 · Cited by 2,309 · cited 1×
“Potential interplay between NETs and platelets in lupus CVD, as has been seen in other models of vascular damage [97,108], also remains to be defined.”
BackgroundPlatelet Activation and Atherothrombosis
Davì, G., & Patrono, C. (2007) · New England Journal of Medicine · doi:10.1056/nejmra071014 · Cited by 2,135
Neutrophil extracellular traps: Is immunity the second function of chromatin?
Brinkmann, V., & Zychlinsky, A. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201203170 · Cited by 1,021 · cited 1×
“As above, NETs represent extracellular chromatin decorated with neutrophil-derived proteins, and presumably function to trap and kill pathogens [93].”
BackgroundAutophagy Regulates Cholesterol Efflux from Macrophage Foam Cells via Lysosomal Acid Lipase
Ouimet, M., Franklin, V., Mak, E., Liao, X., Tabas, I., & Marcel, Y. L. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.03.023 · Cited by 774 · cited 1×
“One recent study [114] did suggest a counter”
BackgroundJung, H., Bobba, R., Su, J., Shariati‐Sarabi, Z., Gladman, D. D., Urowitz, M., Lou, W., & Fortin, P. R. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27289 · Cited by 291 · cited 1×
“Further, in a nested case control study, antimalarials were the only protective factor against thrombovascular events in a multivariate analysis [112], consistent with the antithrombotic effect of these drugs in relevant murine models [113].”
ResultHydroxychloroquine Reverses Thrombogenic Properties of Antiphospholipid Antibodies in Mice
Edwards, M. H., Pierangeli, S., Liu, X., Barker, J. H., Anderson, G., & Harris, E. N. (1997) · Circulation · doi:10.1161/01.cir.96.12.4380 · Cited by 250 · cited 1×
“Further, in a nested case control study, antimalarials were the only protective factor against thrombovascular events in a multivariate analysis [112], consistent with the antithrombotic effect of these drugs in relevant murine models [113].”
ResultUpdate on anti-phospholipid antibodies in SLE: the Hopkins’ Lupus Cohort
Petri, M. (2010) · Lupus · doi:10.1177/0961203309360541 · Cited by 98
Cited by
Obesity in autoimmune diseases: Not a passive bystander
Versini, M., Jeandel, P.-Y., Rosenthal, E., & Shoenfeld, Y. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.07.001 · Cited by 694
Knight, J. S., Luo, W., O’Dell, A. A., Yalavarthi, S., Zhao, W., Subramanian, V., Guo, C., Grenn, R. C., Thompson, P. R., Eitzman, D. T., et al. (2014) · Circulation Research · doi:10.1161/circresaha.114.303312 · Cited by 456
Self-citationKnight, J. S., Subramanian, V., O'Dell, A. A., Yalavarthi, S., Zhao, W., Smith, C. K., Hodgin, J. B., Thompson, P. R., & Kaplan, M. J. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-205365 · Cited by 443
Self-citationExploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Cheng, H. S., Tan, W. R., Low, Z. S., Marvalim, C., Lee, J. Y. H., & Tan, N. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205055 · Cited by 264
Song, L., Wang, Y., Zhang, J., Song, N., Xu, X., & Lu, Y. (2018) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1760-3 · Cited by 205
Antiphospholipid syndrome: an update for clinicians and scientists
Vreede, A. P., Bockenstedt, P. L., & Knight, J. S. (2017) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000410 · Cited by 22
Self-citation
Metadata
- Authors
- Knight, J. S., & Kaplan, M. J.
- Venue
- Current Opinion in Rheumatology
- Published
- 2013-09
- Volume
- 25
- Issue
- 5
- Pages
- 597-605
- ISSN
- 1040-8711 (ISSN-L)
- OpenAlex
- W2070811352
- Cited by
- 82
- References
- 7
- FWCI
- 7.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.